Shares of Acceleron Pharma Inc (NASDAQ:XLRN) have earned an average recommendation of “Buy” from the twenty brokerages that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, six have given a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $46.33.
Several equities analysts recently weighed in on XLRN shares. HC Wainwright boosted their price objective on Acceleron Pharma from $57.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, November 7th. Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a research report on Monday, December 11th. BidaskClub raised Acceleron Pharma from a “hold” rating to a “buy” rating in a research report on Thursday. Credit Suisse Group reissued an “outperform” rating and set a $55.00 price objective on shares of Acceleron Pharma in a research report on Thursday, January 18th. Finally, Cann reissued a “hold” rating on shares of Acceleron Pharma in a research report on Monday, January 8th.
Acceleron Pharma (NASDAQ:XLRN) traded down $0.50 during midday trading on Wednesday, hitting $41.97. The company had a trading volume of 152,200 shares, compared to its average volume of 317,927. Acceleron Pharma has a fifty-two week low of $24.37 and a fifty-two week high of $46.93.
Several institutional investors and hedge funds have recently modified their holdings of XLRN. Quantbot Technologies LP raised its holdings in shares of Acceleron Pharma by 416.3% in the 3rd quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 2,352 shares in the last quarter. Public Employees Retirement Association of Colorado bought a new stake in Acceleron Pharma during the 4th quarter worth approximately $138,000. Amalgamated Bank bought a new stake in Acceleron Pharma during the 4th quarter worth approximately $217,000. Oppenheimer & Co. Inc. bought a new stake in Acceleron Pharma during the 3rd quarter worth approximately $225,000. Finally, PNC Financial Services Group Inc. grew its position in Acceleron Pharma by 57.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $258,000 after acquiring an additional 3,100 shares during the last quarter. 90.13% of the stock is owned by institutional investors and hedge funds.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.